HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $75 price target.
March 15, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics maintains a Buy rating and a $75 price target from HC Wainwright & Co.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically instills confidence in investors, potentially leading to a positive short-term impact on the stock price of Silence Therapeutics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100